Twist Bioscience Corp (TWST) FY2025 10-K Annual Report
Twist Bioscience Corp (TWST) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Nov 17, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Twist Bioscience Corp FY2025 10-K Analysis
Business Overview
- • Core business: Synthetic DNA production and related biotechnological research and manufacturing
- • Strategic real estate expansion: Lease amendment adds 33,000 sq. ft. for R&D, manufacturing, and administration in South San Francisco
- • Lease extended to June 30, 2036 with $119.2M total rent obligations including 3% annual rent escalations
- • $24.4M tenant improvement allowance from landlord to support facility upgrades
- • Option to expand by another 33,000 sq. ft. by December 31, 2026 on fourth floor
Management Discussion & Analysis
- • Revenue $376.6M, up 20% YoY from $313.0M, driven by NGS tools +$39.0M and synthetic genes +$20.9M
- • Gross margin 50.7% vs 42.6%, up 8.1% due to revenue growth and flat fixed manufacturing costs
- • Best segment: NGS tools $208.1M (55% of revenue), worst: DNA libraries $11.2M (3% of revenue)
- • Net cash used in operating activities $47.6M vs $64.1M; capital expenditures $28.0M; financing cash inflow $28.5M including $15.0M from royalty sale
- • Management expects current cash, investments and operations to fund >12 months but may raise financing if needed; significant lease expansion signed through 2036
Risk Factors
- • Regulatory risk: dependency on ISO 27001:2022 cybersecurity certification for information security management systems impacting operations and data protection
- • Geopolitical/macroeconomic risk: exposure to cyberattacks by nation-state actors risking technology theft and operational disruption
- • Operational vulnerability: reliance on single-source supplier for critical DNA synthesis component risking production delays
- • Competitive risk: rivalry with Thermo Fisher Scientific, Illumina, and others who may develop silicon chip synthetic DNA technologies threatening market position
- • Financial risk: accumulated deficit $1,319.6M and net losses $204.6M-$208.7M in prior years raising sustainability concerns
Twist Bioscience Corp FY2025 Key Financial MetricsXBRL
Revenue
$377M
▲ +20.3% YoY
Net Income
-$78M
▲ +62.8% YoY
Operating Margin
-36.2%
▲ +3437bp YoY
Net Margin
-20.6%
▲ +4607bp YoY
ROE
-16.4%
▲ +2773bp YoY
Total Assets
$642M
▲ +4.5% YoY
EPS (Diluted)
$-1.30
▲ +63.9% YoY
Operating Cash Flow
-$48M
▲ +25.7% YoY
Source: XBRL data from Twist Bioscience Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Twist Bioscience Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.